Myla Lai Goldman
Founder at GeneCentric Therapeutics, Inc.
Myla Lai Goldman active positions
Companies | Position | Start | End |
---|---|---|---|
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | Private Equity Investor | - | - |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | Chairman | 2021-06-30 | - |
Founder | 2021-06-30 | - |
Career history of Myla Lai Goldman
Training of Myla Lai Goldman
University of Pennsylvania | Graduate Degree |
Columbia University Vagelos College of Physicians & Surgeons | Doctorate Degree |
Statistics
International
United States | 5 |
Operational
Graduate Degree | 1 |
Private Equity Investor | 1 |
Doctorate Degree | 1 |
Sectoral
Consumer Services | 3 |
Finance | 2 |
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 2 |
---|---|
Hatteras Venture Partners
Hatteras Venture Partners Investment ManagersFinance Hatteras Venture Partners (Hatteras Venture) is venture capital firm founded in 2000 by Clay B. Thorp and John Crumpler. The firm is headquartered in Durham, North Carolina. | Finance |
GeneCentric Therapeutics, Inc.
GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | Health Technology |
- Stock Market
- Insiders
- Myla Lai Goldman
- Experience